Register Login

ABVC BIOPHARMA, INC. (ABVC)

SymbolABVC
NameABVC BIOPHARMA, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address44370 OLD WARM SPRINGS BLVD., FREMONT, California, 94538, United States
Telephone+1 510 - 668-0881
Fax—
Email—
Website—
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001173313
Description

ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes that represent enormous commercial potential.

Additional info from NASDAQ:
ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes that represent enormous commercial potential.

2026-08-27 12:30

(99% Neutral) ABVC BIOPHARMA, INC. (ABVC) Announces Regulatory Update

Read more
2026-08-25 17:31

New Form PRER14A - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-08-25 <b>AccNo:</b> 0001213900-26-093538 <b>Size:</b> 231 KB

Read more
2026-08-17 17:20

New Form 424B4 - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001213900-26-090779 <b>Size:</b> 956 KB

Read more
2026-08-17 17:19

New Form 424B4 - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001213900-26-090778 <b>Size:</b> 956 KB

Read more
2026-08-17 17:18

New Form 424B4 - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001213900-26-090777 <b>Size:</b> 956 KB

Read more
2026-08-17 17:17

New Form 424B4 - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001213900-26-090775 <b>Size:</b> 956 KB

Read more
2026-08-12 12:50

New Form 8-K/A - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001213900-26-088165 <b>Size:</b> 187 KB <br />Item 8.01: Other Events

Read more
2026-07-28 17:31

New Form PRE 14A - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-07-28 <b>AccNo:</b> 0001213900-26-082298 <b>Size:</b> 204 KB

Read more
2026-05-15 18:00

New Form NT 10-Q - ABVC BIOPHARMA, INC. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001213900-26-057917 <b>Size:</b> 22 KB

Read more
2026-03-27 20:05

(99% Neutral) ABVC BIOPHARMA, INC. (ABVC) Files Form 8-K

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT05414747 Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular E… Na Retinal Detachment Suspended 2023-04-15 2025-12-15 ClinicalTrials.gov
NCT05202327 PDC-1421 Treatment in Adult Patients With ADHD Phase2 Attention-Deficit Hyperactivity Disorder (ADHD) Completed 2022-04-07 2024-04-08 ClinicalTrials.gov
Total clinical trials: 2
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Placebo Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
Placebo Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
Placebo Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
Placebo Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
Placebo Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
Placebo Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
Placebo Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
Placebo Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
SF6 Gas Other Approved Retinal Detachment SUSPENDED NCT05414747
ABV-1701 Other Approved Retinal Detachment SUSPENDED NCT05414747
Placebo Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule Other Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
SF6 Gas DEVICE Approved Retinal Detachment SUSPENDED NCT05414747
ABV-1701 DEVICE Approved Retinal Detachment SUSPENDED NCT05414747
Placebo DRUG Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
PDC-1421 Capsule DRUG Phase PHASE2 Attention-Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT05202327
Total products: 24